INTRODUCTION {#S1}
============

Mammalian genomes contain a high density of repetitive DNA elements, such as long interspersed elements and short interspersed elements ([@R1]; [@R20]). Indeed, the human genome includes approximately one million copies of *Alu*-like short interspersed elements ([@R5]; [@R10]; [@R20]; [@R21]; [@R83]). Such repetitive elements have the potential to recombine, thereby causing chromosomal rearrangements. In particular, two repetitive elements on the same chromatid can recombine to cause a deletion rearrangement, which we refer to as a repeat-mediated deletion (RMD). RMDs have been found to cause several rearrangements associated with human disease ([@R22]). For example, RMDs between *Alu* elements have been found to disrupt tumor suppressor genes, such as *BRCA1* and *MSH2* ([@R41]; [@R64]; [@R65]).

RMD events in humans can span a wide array of distances between the repeats, as well as varying degrees of homology between the repeats (i.e., sequence divergence). A survey of \>200 rearrangements involving two *Alu* elements, used to develop a predictive computational model for such rearrangements, showed that *Alu*-mediated deletions can be as short as \<1 kilobase pair (kbp) to over 4 megabase pairs (Mbp), although the vast majority were \<57 kbp ([@R74]). Furthermore, this survey of *Alu*-mediated rearrangements uncovered a bias for events involving evolutionarily younger *Alu* elements ([@R74]), which generally have low sequence divergence ([@R5]). Accordingly, examining how repeat distance and sequence divergence affect RMD mechanisms will provide insight into the etiology of these rearrangements. Similarly, the distance between the initiating DNA lesion(s) and each of the repeats likely affects the mechanism of RMDs.

One model for RMD formation is repair of a DNA double-strand break (DSB) that uses annealing of two flanking repeats to bridge the DSB, resulting in the deletion of one of the repeats and the intervening sequence. This model for RMD formation is referred to as single-strand annealing (SSA) ([@R7]; [@R53]). Based on this model, a key step of RMD formation that is affected by DSB/repeat distance is end resection, which refers to the processing of DSBs into 3′ single-stranded DNA (ssDNA) that reveals the repeats used for repair ([@R80]). As the distance between the DSB and each repeat increases, so does the length of end resection that is required for each repeat to be revealed in ssDNA for the annealing step. Consistent with this model, factors important for end resection promote RMDs, including CtIP and its ortholog *SAE2* in the yeast *Saccharomyces cerevisiae* (*S. cerevisiae*) ([@R6]; [@R50]; [@R51]; [@R72]; [@R92]). Also in *S. cerevisiae*, the nucleases *EXO1* and *DNA2*, along with the *SGS1* RecQ-helicase, are important for extensive end resection and RMD events ([@R51]; [@R92]).

Also based on the SSA model, after end resection, the repeats are synapsed to form an annealing intermediate. When divergent repeats are annealed together, the double-stranded DNA (dsDNA) contains mismatched bases and hence forms a heteroduplex. This intermediate is prone to reversal by heteroduplex rejection, which is mediated by proteins in the mismatch repair pathway ([@R2]; [@R29]; [@R79]; [@R85]). For example, MSH2 is important to suppress RMDs, and other homologous recombination events, between divergent sequences ([@R25]; [@R29]; [@R50]; [@R79]). Another factor important for heteroduplex rejection in *S. cerevisiae* is *SGS1* ([@R29]; [@R76]; [@R79]). However, as mentioned above, *SGS1* also is important for end resection and as such appears to have contrary roles in RMD formation in yeast.

The mammalian ortholog of *SGS1* that influences these steps of RMDs (i.e., end resection and/or heteroduplex rejection) has been unclear, because there are five mammalian RecQ-helicases ([@R18]). A possible candidate is the BLM helicase, which is found mutated in the inherited disease Bloom's syndrome ([@R26]). BLM has long been linked to suppression of homologous recombination, because BLM-deficient cell lines show a high frequency of sister chromatid exchanges ([@R13]). The BLM protein can unwind a variety of DNA structures, including displacement loop recombination intermediates ([@R4]). This unwinding activity is likely central to BLM-mediated suppression of sister chromatid exchanges and furthermore has recently been implicated in dissolution of recombination intermediates during alternative lengthening of telomeres ([@R47]; [@R62]; [@R73]). However, BLM was shown to have no obvious effect on DSB-induced homologous recombination in mouse and human cells, including between \~1.5% divergent sequences ([@R43]). Although, BLM was shown to inhibit DSB-induced homologous recombination events in human cells involving repeats with 19% sequence divergence ([@R86]), indicating a possible role for BLM on heteroduplex rejection with very high sequence divergence. However, the parameters that determine the role of BLM on heteroduplex rejection are poorly defined. Regarding the end resection step of RMDs, although BLM is substantially active in biochemical assays for this process ([@R19]; [@R59]; [@R75]), the relative importance of this factor in cells to promote end resection during chromosomal DSB repair is unclear.

We posited that the influence of BLM on RMD formation may be affected by DSB/repeat distance and repeat divergence. Based on the SSA model, the DSB/repeat distance defines the length of end resection that is required for an RMD. Furthermore, this DSB/repeat distance affects the length of the non-homologous flanking sequence in the annealing intermediate, which we posited might influence heteroduplex rejection. Thus, we have examined how these various features of RMDs affect the relative role of BLM and other factors (e.g., EXO1, DNA2, MSH2, and the DNA annealing factor RAD52) on these repair events.

RESULTS {#S2}
=======

BLM Promotes RMDs Induced by Chromosomal DSBs Far from a Homologous Repeat but Markedly Suppresses RMDs with Intermediate DSB/Repeat Distances, Particularly with Divergent Repeats {#S3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We have investigated the influence of the BLM helicase on RMD formation. For this, we used a previously described reporter system (RMD-GFP; [Figure 1A](#F1){ref-type="fig"}), in which a 287-bp fragment of the *Cdkn1a* gene is fused to GFP and integrated into the *Pim1* locus on chromosome 17 in mouse embryonic stem cells (mESCs) ([@R50]). Introducing this 287-bp fragment of the *Cdkn1a* gene at the *Pim1* locus creates two tandem repeats, (shown as R in [Figure 1A](#F1){ref-type="fig"}), which are similar in size to human *Alu* elements ([@R5]). An RMD event between these two repeats generates a *Cdkn1a-GFP* fusion gene, causing GFP expression that can be detected with flow cytometry. The *Cdkn1a* locus is 0.4 Mbp upstream of the *Pim1* locus, such that we generate two Cas9 DSBs to induce RMDs: the first DSB is 268 bp downstream of the 5′ repeat in the *Cdkn1a* locus and the second DSB is various distances upstream of the 3′ repeat in the *Pim1* locus (3′-DSB/repeat distances of 16 bp, 3.3 kbp, 9.1 kbp, 19 kbp, and 28.4 kbp). We created two variants of this assay, in which the 3′ repeat has three and eight point mutations, which causes 1% and 3% sequence divergence, respectively. In a prior study from our laboratory, we validated the single-guide RNAs (sgRNAs) targeting Cas9-induced DSBs to the various positions, as well as the structure of the RMD events from sorted GFP+ cells ([@R50]).

To examine the influence of BLM on these RMD events, we treated cells with a pool of four small interfering RNAs (siRNAs) targeting BLM (siBLM), which we confirmed depletes BLM via immunoblotting ([Figure 1B](#F1){ref-type="fig"}). Control cells are treated with non-targeting siRNA (siCTRL). We first tested RMDs with identical repeats and found that siBLM had no effect on these events at the 3′-DSB/repeat distances of 16 bp and 9.1 kbp but caused an increase for the 3.3-kbp distance ([Figure 1C](#F1){ref-type="fig"}; 1.8-fold). In contrast, we found that siBLM caused a reduction in RMDs for the 19-kbp and 28.4-kbp 3′-DSB/repeat distances (2-fold and 4.6-fold, respectively). We then examined RMDs with 1% and 3% sequence divergence. For the 1% divergent RMDs, siBLM caused a marked increase for these events for 16-bp, 3.3-kbp, and 9.1-kbp 3′-DSB/repeat distances (2.5-, 4.8-, and 5.1-fold, respectively). In contrast, siBLM had no effect for the 19-kbp distance and, as with the identical repeats, caused a reduction for the 28.4-kbp distance (2.9-fold). For the 3% divergent RMDs, siBLM caused a substantial increase in these events for the 16-bp, 3.3-kbp, and 9.1-kbp 3′-DSB/repeat distances (2-, 7.8-, and 10.6-fold, respectively) but, in this case, also caused an increase at 19 kbp (2.9-fold) and had no effect at 28.4 kbp ([Figure 1C](#F1){ref-type="fig"}). Notably, for both 1% and 3% divergent RMDs, siBLM caused a greater increase for the intermediate DSB/repeat distances (3.3 kbp and 9.1 kbp) than the short distance (16 bp).

We also examined BLM using a different method: an mESC line that allows for repression of endogenous BLM expression using doxycycline (Dox) treatment, due to replacement of the *Blm* promoter on both alleles with a Dox-responsive cassette (*Blm*^*tet/tet*^ mESCs; [@R90]). We confirmed that Dox treatment in *Blm*^*tet/tet*^ mESCs causes depletion in BLM protein, compared to vehicle (DMSO; [Figure 1B](#F1){ref-type="fig"}). We also found that, in the control conditions (DMSO), BLM levels are substantially higher than wild-type (WT) mESCs ([Figure 1B](#F1){ref-type="fig"}), which is likely due to the Dox-responsive cassette that uses the tetracycline transactivator ([@R8]). Accordingly, this cell line facilitates a comparison of overexpression of BLM versus loss of BLM (control versus Dox-treated, respectively). With this *Blm*^*tet/tet*^ mESC line, the RMD reporters were integrated and cells were pre-treated with DMSO or Dox prior to transfection with the sgRNA/Cas9 plasmids and then treated with DMSO or Dox until analysis.

We first tested the *Blm*^*tet/tet*^ cell line with the RMD reporter with identical repeats and found that Dox treatment caused a marked increase in RMD frequency at the 3′-DSB/repeat distances of 3.3 kbp and 9.1 kbp ([Figure 1D](#F1){ref-type="fig"}; 4.5-fold and 3.4-fold, respectively). Furthermore, Dox treatment caused a modest increase in RMD frequencies at the 3′-DSB/repeat distances of 16 bp and 19 kbp ([Figure 1D](#F1){ref-type="fig"}; 1.2- and 1.5-fold, respectively). In contrast, we found that Dox treatment caused a decrease in RMD frequency at the 28.4-kbp 3′-DSB/repeat distance (1.6-fold). With both 1% and 3% sequence divergence, we found that Dox treatment caused a significant increase in RMDs at all 3′-DSB/repeat distances; however, the fold effects were affected by the distance. Specifically, Dox treatment caused a dramatic increase in RMDs with 1% and 3% divergence for the 3.3-kbp and 9.1-kbp distances, but the effects were lower for the 16-bp, 19-kbp, and 28.4-kbp distances ([Figure 1D](#F1){ref-type="fig"}).

We then compared the findings between these two approaches for manipulating BLM levels. As mentioned above, the control condition for the *Blm*^*tet/tet*^ mESCs reflects overexpression of BLM compared to WT. Consistent with elevated levels of BLM, *Blm*^*tet/tet*^ mESCs show lower RMD frequencies for several events compared to WT ([Figure S1A](#SD1){ref-type="supplementary-material"}). In comparing fold effects between the two approaches, we found that Dox treatment in the *Blm*^*tet/tet*^ mESCs caused a more dramatic increase in RMDs compared to siBLM ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). However, the overall pattern of effects of 3-DSB/repeat distance and repeat divergence were similar ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). With both methods, BLM has the most profound effect on inhibiting RMDs at intermediate 3′-DSB/repeat distances (i.e., 3.3 kbp and/or 9.1 kbp), which was substantially magnified with sequence divergence. In contrast, this inhibitory effect of BLM was diminished for the short 3′-DSB/repeat distance (i.e., 16 bp). Finally, for the long 3′-DSB/repeat distances (19 kbp and 28.4 kbp), BLM either promoted these events or the inhibitory role was markedly diminished compared to the intermediate distances (i.e., 3.3 kbp and/or 9.1 kbp).

We also tested expression of human BLM WT versus a mutant that is disrupted in the ATP-binding site in the helicase domain (K695A/D795A; [@R70]; [@R88]) in siBLM-treated cells. We first examined RMDs with 1% and 3% divergence at the 9-kbp 3′-DSB/repeat distance, which are increased by BLM depletion ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). We found that expression of human BLM WT caused a marked decrease in these events compared to both the control empty vector (EV) and the K695A/D795A mutant ([Figure S1B](#SD1){ref-type="supplementary-material"}). We also examined RMDs with identical repeats for the 28.4-kbp 3′-DSB/repeat distance, which is decreased by BLM depletion ([Figures 1C](#F1){ref-type="fig"}, [1D](#F1){ref-type="fig"}, and [S1B](#SD1){ref-type="supplementary-material"}), and found that expression of human BLM WT and K695A/D795A had no obvious effect ([Figure S1B](#SD1){ref-type="supplementary-material"}). We suggest that expression of human BLM WT did not cause an increase in these RMDs, because overexpression of BLM causes a shift toward inhibition of RMDs, as shown above for the comparison of *Blm*^*tet/tet*^ versus WT ([Figure S1A](#SD1){ref-type="supplementary-material"}). In summary, these findings support the above conclusion that, for long DSB/repeat distances, BLM either promotes these events or the inhibitory effect is diminished. Furthermore, these findings indicate that BLM-mediated suppression of RMDs requires the helicase domain.

We also performed additional controls with BLM depletion. To test for possible effects on Cas9-induced DSBs, we used the Surveyor nuclease assay to examine mutagenic end joining at a Cas9 target site ([@R50]) and found no obvious effect with either approach to deplete BLM ([Figure S2A](#SD1){ref-type="supplementary-material"}). We also found that BLM depletion by either approach did not affect cell cycle profiles ([Figure S2B](#SD1){ref-type="supplementary-material"}).

The DSB End Resection Factors EXO1 and DNA2 Are Particularly Important for RMDs with Long 3′-DSB/Repeat Distances, Similar to BLM {#S4}
---------------------------------------------------------------------------------------------------------------------------------

The above findings indicate that RMDs at long 3′-DSB/repeat distances can be promoted by BLM, which we posited might indicate a role for BLM in extensive DSB end resection ([@R80]). A corollary of this hypothesis is that other factors important for extensive end resection may also be particularly required for such RMDs. To test this hypothesis, we examined EXO1 and DNA2, which were shown in *S. cerevisiae* to have redundant functions in promoting DSB end resection ([@R31]; [@R51]; [@R92]). Other studies have also implicated mammalian EXO1 and DNA2 in DSB end resection ([@R31]; [@R39]; [@R59]; [@R78]; [@R82]).

To examine DNA2, we used a pool of four siRNA-targeting DNA2 (siDNA2), which we confirmed depletes DNA2 mRNA ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). With RMDs between identical repeats, siDNA2 caused a substantial decrease in RMDs for the long 3′-DSB/repeat distances (19 kbp and 28.4 kbp). In contrast, siDNA2 caused a modest reduction for the 9.1 kbp (1.3-fold) and had no effect at the 3.3-kbp and 16-bp 3′-DSB/repeat distances ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). For the 1% divergent RMD events, we found a similar pattern: siDNA2 did not cause a decrease in RMDs for the short/intermediate 3′-DSB/repeat distances (no effect at 16 bp and 9 kb and a modest increase at 3.3 kbp) but caused a significant reduction in RMD frequency for the long distances (1.9-fold for 19 kbp and 2.1-fold for 28.4 kbp). For the 3% divergent RMD events, we found that siDNA2 had no significant effect. Thus, DNA2 appears to promote RMDs between identical and 1% divergent repeats, specifically at long DSB/repeat distances. We also examined expression of 3xFLAG-tagged human DNA2 WT and three mutants deficient in the nuclease, helicase, or both domains (i.e., D277A, K654A, and D277A/K654A, respectively; [Figure 2C](#F2){ref-type="fig"}; [@R67]), because these domains are important for DNA replication ([@R24]; [@R45]). We examined RMDs between identical repeats at the 28.4-kbp distance, which is reduced with siDNA2 ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). We found that DNA2 WT caused a substantial increase in these RMDs (4-fold), K654A caused a slight increase (1.3-fold), and D277A and D277A/K654A failed to cause an increase versus control EV (expression confirmed by FLAG immunoblot; [Figure 2C](#F2){ref-type="fig"}). Thus, both the DNA2 nuclease and helicase domains appear important for promoting RMDs with a long DSB/repeat distance.

To examine EXO1, we integrated the RMD-GFP reporters in *Exo1*^*−/−*^ mESCs ([@R16]) and conducted the RMD assays along with an EXO1 complementation vector or control EV. With RMDs between identical repeats, *Exo1*^*−/−*^ versus WT mESCs showed a marked reduction in these events for long 3′-DSB/repeat distances (2.8-fold for 19 kbp and 3.8-fold for 28.4 kbp), which was reversed upon complementation with EXO1 ([Figure 2D](#F2){ref-type="fig"}). For the intermediate 3′-DSB/repeat distances, *Exo1*^*−/−*^ showed reduced frequencies versus WT, but the fold effects were lower than for the long distances (i.e., 1.8-fold for 9.1 kbp and 1.6-fold for 3.3 kbp) and furthermore were not restored by EXO1 complementation. Finally, for 16 bp, RMD frequencies were not distinct between *Exo1*^*−/−*^ versus WT. For the 1% and 3% RMD reporters, we found that *Exo1*^*−/−*^ did not show a reduction in RMD frequency at any of the 3′-DSB/repeat distances compared to WT ([Figure 2D](#F2){ref-type="fig"}). We then compared expression of EXO1 WT to a mutant deficient in exonuclease activity (D173A; [@R61]) for the RMD between identical repeats and the 28.4-kbp distance and found that only EXO1 WT was proficient at promoting this event (expression confirmed by immunoblotting; [Figure 2E](#F2){ref-type="fig"}). These results indicate that EXO1 is required for RMDs between identical repeats at long DSB/repeat distances, similar to DNA2 and BLM, and that EXO1 nuclease activity is important for this function.

The Influence of EXO1 on Promoting RMDs Is Not Epistatic with the Effect of DNA2 and BLM and Is Consistent with a Role in End Resection {#S5}
---------------------------------------------------------------------------------------------------------------------------------------

In several reports, EXO1 has been shown to have redundant functions with DNA2 and SGS1/BLM for DSB end resection ([@R31]; [@R51]; [@R92]). Thus, we tested whether depletion of DNA2 and BLM might further reduce RMD frequencies in *Exo1*^*−/−*^ mESCs. We focused on RMDs between identical repeats, as these were the events promoted by these factors, particularly for the long 3′-DSB/repeat distances ([Figures 1C](#F1){ref-type="fig"}, [1D](#F1){ref-type="fig"}, [2A](#F2){ref-type="fig"}, and [2D](#F2){ref-type="fig"}). We confirmed that treatment of siDNA2 and siBLM in *Exo1*^*−/−*^ mESCs caused depletion of DNA2 mRNA and BLM protein ([Figure 3A](#F3){ref-type="fig"}). We also determined that such siRNAs and EXO1 loss had no obvious effect on cell cycle profiles versus WT ([Figure S2B](#SD1){ref-type="supplementary-material"}). We found that siDNA2 in *Exo1*^*−/−*^ mESCs caused a decrease in RMDs at all 3′-DSB/repeat distances ([Figure 3B](#F3){ref-type="fig"}). This effect was modest at 16-bp and 3.3-kbp 3′-DSB/repeat distances (1.3-fold or 1.6-fold, respectively) and more substantial ≥9.1 kbp (i.e., ≥2.7-fold). For example, for the 19-kbp distance, combined loss of DNA2 and EXO1 caused an 18-fold reduction in RMD frequency compared to WT ([Figure 3B](#F3){ref-type="fig"}). We then examined BLM and found that siBLM in *Exo1*^*−/−*^ mESCs also led to a marked reduction in RMD frequency for the long 3′-DSB/repeat distances (4.4-fold at 19 kbp and 3.3-fold at 28.4 kbp; [Figure 3B](#F3){ref-type="fig"}). Thus, for the long 3′-DSB/repeat distances, combined loss of EXO1 and BLM also caused a drastic reduction in RMD frequency compared to WT (\>10-fold; [Figure 3B](#F3){ref-type="fig"}). Furthermore, with *Exo1*^*−/−*^ mESCs treated with siBLM, expression of human BLM WT caused a significant increase in RMDs with the 28.4-kbp 3′-DSB/repeat distance ([Figure S1B](#SD1){ref-type="supplementary-material"}). In comparing the helicase-deficient mutant (K695A/D795A) versus BLM WT in this experiment, the RMD frequency for the mutant was slightly lower, but not statistically different ([Figure S1B](#SD1){ref-type="supplementary-material"}). For the shorter 3′-DSB/repeat distances, siBLM treatment in *Exo1*^*−/−*^ mESCs caused no significant effects at the 3′-DSB/repeat distances of 3.3 kbp and 16 bp and a modest (1.5-fold) decrease at 9.1 kbp ([Figure 3B](#F3){ref-type="fig"}). In summary, combined disruption of DNA2 and EXO1, and BLM and EXO1, causes a drastic reduction in RMDs at long DSB/repeat distances.

We also examined CtIP, which is important for initiation of end resection ([@R72]), by depleting CtIP alone (siCtIP) and in combination with siBLM. Similar to the findings in the prior study with the RMD-GFP reporter ([@R50]), we found that siCtIP caused a marked decrease in RMDs at all 3′-DSB/repeat distances (≥3.1-fold; [Figure S3](#SD1){ref-type="supplementary-material"}). Thus, CtIP-mediated initiation of end resection is important for RMD events irrespective of 3′-DSB/repeat distances. Adding siBLM with siCtIP caused a significant increase in RMDs at the intermediate distances (3.3 kbp and 9.1 kbp), and a modest decrease at the 28.4-kbp distance, as compared to siCtIP alone ([Figure S3](#SD1){ref-type="supplementary-material"}). This finding supports the notion that BLM and CtIP have distinct effects on RMDs.

We sought to contrast our findings with RMD events versus detection of end resection via a flow-cytometry-based assay for chromatin-bound RPA (an ssDNA binding factor), which also includes staining with the DNA dye DAPI to examine cell cycle phase ([@R28]). To induce DSBs, we used the topoisomerase II poison etoposide ([@R60]), which we found caused a significant increase in WT mESCs with high chromatin-bound RPA ([Figure 3C](#F3){ref-type="fig"}). For *Exo1*^*−/−*^, and WT treated with siDNA2, we observed a significant reduction in such RPA staining after etoposide treatment compared to WT siCTRL ([Figure 3C](#F3){ref-type="fig"}). We found that siDNA2 treatment of *Exo1*^*−/−*^ cells did not have an obvious effect; however, RPA staining in *Exo1*^*−/−*^ cells treated with etoposide was near background levels ([Figure 3C](#F3){ref-type="fig"}). Finally, siBLM-treated cells were not distinct from siCTRL for both WT and *Exo1*^*−/−*^ (etoposide treated cells; [Figure 3C](#F3){ref-type="fig"}). These findings support a role for EXO1 and DNA2 in DSB end resection in mESCs. In contrast, the roles of BLM in DSB end resection were not readily revealed by this assay, which may reflect an anti-recombination activity of BLM that could stabilize RPA-bound ssDNA.

BLM-Mediated Suppression of RMDs Is Not Epistatic with the Influence of MSH2 (except at the 16-bp Distance) or BRCA2 {#S6}
--------------------------------------------------------------------------------------------------------------------

We next sought to compare BLM to another factor that inhibits RMDs between divergent repeats: the mismatch repair factor MSH2 ([@R50]). In particular, we tested whether BLM and MSH2 are epistatic for inhibiting such RMDs, using siBLM treatment in *Msh2*^*−I−*^ mESCs, which we confirmed causes a reduction in BLM protein levels ([Figure 4A](#F4){ref-type="fig"}). For RMDs with identical repeats, we compared *Msh2*^*−I−*^ mESCs to WT and found that loss of MSH2 affected RMD frequencies for the 3′-DSB/repeat distances of 3.3 and 28.4 kbp (2.1-fold higher and 1.8-fold lower, respectively) but had no effect at the other distances ([Figure 4A](#F4){ref-type="fig"}). We then examined the effect of siBLM in *Msh2*^*−I−*^ mESCs and found similar results to siBLM in WT, i.e., a marked reduction in RMDs for long 3′-DSB/repeat distances (4.9-fold for 19 kbp and 7.7-fold for 28.4 kbp; [Figure 4A](#F4){ref-type="fig"}). Also in *Msh2*^*−I−*^ mESCs, siBLM caused modest effects at 16 bp and 3.3 kbp (1.5-fold lower and 1.1-fold higher, respectively) and no effect at 9.1 kbp ([Figure 4A](#F4){ref-type="fig"}).

For the 1% and 3% divergent repeats, we found that *Msh2*^*−I−*^ mESCs showed a marked increase in RMD frequency at all 3′-DSB/repeat distances compared to WT (≥4-fold), as expected ([@R36]; [@R50]). Strikingly, we found that siBLM in *Msh2*^*−I−*^ mESCs caused a further increase in RMD frequency between 1% or 3% divergent repeats at 3.3 kbp and 9.1 kbp (≥3.1-fold; [Figure 4A](#F4){ref-type="fig"}). Thus, combined loss of MSH2 and BLM causes a dramatic increase in RMDs between divergent repeats at these intermediate 3′-DSB/repeat distances (≥21-fold; [Figure 4A](#F4){ref-type="fig"}). We then examined the long 3′-DSB/repeat distances. We found that, for the 1% divergent repeats, siBLM treatment in *Msh2*^*−I−*^ mESCs caused a decrease in RMDs (1.5-fold for 19 kbp and 2.2-fold for 28.4 kbp; [Figure 4A](#F4){ref-type="fig"}). For the 3% divergent repeats, siBLM caused a modest increase at 19 kbp (1.4-fold) and had no effect at 28.4 kbp ([Figure 4A](#F4){ref-type="fig"}). Importantly, siBLM treatment in *Msh2*^*−I−*^ mESCs did not have a substantial effect on RMDs with the short 3′-DSB/repeat distance (16 bp; [Figure 4A](#F4){ref-type="fig"}), which is distinct from the effect of siBLM in WT cells (i.e., caused an increase for the divergent repeats; [Figure 1C](#F1){ref-type="fig"}). These findings indicate that BLM and MSH2 are not epistatic for inhibiting RMDs between divergent repeats with intermediate 3′-DSB/repeat distances (i.e., 3.3 kbp and 9.1 kbp) but are epistatic for the short distance (16 bp). Furthermore, in MSH2-deficient cells, BLM promotes RMDs with long 3′-DSB/repeat distances, as in WT cells.

We also sought to contrast the role of BLM in these RMD events with another homologous recombination pathway, homology-directed repair (HDR), using the DR-GFP reporter ([@R54]). For these experiments, we induced the DSB in this reporter using Cas9 and a sgRNA ([@R56]), to be consistent with the RMD analysis. We used the *Blm*^*tet/tet*^ cell line with the DR-GFP reporter targeted to the *Pim1* locus and found that BLM depletion did not obviously affect the frequency of HDR ([Figure 4B](#F4){ref-type="fig"}), similar to prior findings with another HDR assay ([@R43]). In contrast, depletion of BRCA2 via a pool of four siRNAs (siBRCA2) caused a significant reduction in this HDR event ([Figure 4C](#F4){ref-type="fig"}), as expected ([@R54]).

We then examined the influence of BRCA2 on RMDs in BLM-proficient and deficient cells. For this, we treated the *Blm*^*tet/tet*^ RMD reporter cell lines with siBRCA2, which we confirmed causes depletion of BRCA2 protein ([Figure 4D](#F4){ref-type="fig"}). We found that siBRCA2 depletion caused an increase in RMDs between identical repeats at the intermediate 3′-DSB/repeat distances (3.3 kbp and 9.1 kbp; the latter statistically significant only without multiple comparison correction) both in the Dox-treated and control (DMSO-treated) cells ([Figure 4E](#F4){ref-type="fig"}). Similarly, siBRCA2 treatment caused an increase in RMDs for the 1 % divergent repeats at several 3′-DSB/repeat distances in both the Dox-treated and control cells ([Figure 4E](#F4){ref-type="fig"}; although some are significant only without multiple comparison correction). For the 3% divergent repeats, siBRCA2 had minimal effects ([Figure 4E](#F4){ref-type="fig"}). Altogether, these findings indicate that BRCA2 can suppress a subset of RMDs, which is consistent with prior findings ([@R50]; [@R77]; [@R84]). Furthermore, the influence of BRCA2 appears independent of BLM.

RAD52 Substantially Promotes a Subset of RMDs; however, BLM and MSH2 Inhibit RMDs Independently of RAD52 {#S7}
--------------------------------------------------------------------------------------------------------

We next sought to examine the interplay between BLM and RAD52 on RMD formation. RAD52 is a DNA binding protein that can mediate annealing between homologous sequences ([@R9]; [@R32]). Previously, using a *Rad52*^*−/−*^ mESC line, our laboratory showed that RAD52 promotes RMDs between identical repeats at 3′-DSB/repeat distances of ≥3.3 kbp but does not promote such RMDs at the 16-bp distance ([@R50]). We confirmed these findings by comparing *Rad52*^*−/−*^ cells with both WT and *Rad52*^*−/−*^ cells transfected with a RAD52 expression vector, which causes overexpression of RAD52, as well as higher RMD frequencies than WT ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). We then examined RMDs with 1% divergent repeats and found similar results, in that RAD52 is markedly required for such RMDs at 3′-DSB/repeat distances of ≥3.3 kbp ([Figure 5B](#F5){ref-type="fig"}). For the 3% divergent repeats, loss of RAD52 caused a significant decrease for the 3.3-kbp and 9.1-kbp distances (the former only when not adjusted for multiple comparisons; [Figure 5B](#F5){ref-type="fig"}). Also, RAD52 expression in the *Rad52*^*−/−*^ mESCs caused a striking increase in RMDs with 3% divergent repeats for 3′-DSB/repeat distances ≥3.3 kbp ([Figure 5B](#F5){ref-type="fig"}). For the 16-bp 3′-DSB/repeat distance, we found that loss of RAD52 failed to cause a reduction of RMDs between identical or divergent repeats ([Figure 5B](#F5){ref-type="fig"}). Thus, RAD52 is critical for RMDs with 3′-DSB/repeat distances ≥3.3 kbp, but its requirement appears diminished with 3% divergent repeats, although overexpression of RAD52 can promote these events.

We then tested whether the role of RAD52 in RMDs is epistatic with BLM and/or MSH2. As one possibility, loss of BLM and/or MSH2 might fail to cause an increase in RMDs in *Rad52*^*−/−*^ mESCs. These findings would indicate that BLM and/or MSH2 specifically disrupt the RAD52 annealing intermediate. Alternatively, loss of BLM and/or MSH2 might cause an increase in RMDs in *Rad52*^*−/−*^ mESCs. Such findings would indicate that suppression of RMDs via BLM and/or MSH2 is not specific to RAD52 annealing intermediates.

Thus, we examined the effects of siBLM in *Rad52*^*−*/*−*^ mESCs, which we confirmed caused depletion of BLM ([Figure 5A](#F5){ref-type="fig"}). From these experiments, we found that siBLM treatment of *Rad52*^*−/−*^ mESCs caused a drastic increase in RMDs between 1% and 3% divergent repeats for the 3.3-kbp and 9.1-kbp 3′-DSB/repeat distances (≥6.8-fold; [Figure 5C](#F5){ref-type="fig"}). We also found that siBLM treatment in *Rad52*^*−/−*^ mESCs caused a significant but less dramatic increase for RMD events with identical repeats for the 3.3-kbp and 9.1-kbp 3′-DSB/repeat distances (≥2-fold) and for divergent repeats for the 16-bp distance (≤ 2-fold; [Figure 5C](#F5){ref-type="fig"}). Thus, the role of BLM for inhibiting RMDs appears independent of RAD52. For RMDs with long 3′-DSB/repeat distances and identical repeats, whereas siBLM treatment of WT cells caused a reduction in these events ([Figure 1C](#F1){ref-type="fig"}), siBLM treatment of *Rad52*^*−/−*^ mESCs failed to cause such a decrease ([Figure 5C](#F5){ref-type="fig"}). However, these RMD events in *Rad52*^*−/−*^ mESCs are near background levels (i.e., ≥ 17-fold lower versus WT).

We then performed analogous experiments with MSH2 and RAD52, using a *Rad52*^*−/−*^*Msh2−/−* mESC line that we generated ([Figure 5A](#F5){ref-type="fig"}), and determined that loss of MSH2 and/or RAD52 did not obviously affect cell cycle profiles ([Figure S2B](#SD1){ref-type="supplementary-material"}). For the RMD analysis, an MSH2 expression vector was used, which we confirmed expresses MSH2 ([Figure 5A](#F5){ref-type="fig"}). We found similar effects of MSH2 when comparing either *Rad52−/− Msh2*^*−/−*^ versus *Rad52*^*−/−*^ or *Rad52*^*−/−*^*Msh2*^*−/−*^ versus the MSH2 complemented ([Figure 5D](#F5){ref-type="fig"}). For the 1% and 3% divergent repeats, we found that loss of MSH2 in RAD52-deficient cells caused a marked increase in RMDs at all 3′-DSB/repeat distances ([Figure 5D](#F5){ref-type="fig"}). Indeed, we found that RMD frequencies were restored to WT levels for 1% divergent repeats in *Rad52*^*−/−*^*Msh2*^*−/−*^ mESCs and were even higher than WT levels for 3% divergent repeats in *Rad52*^*−/−*^*Msh2*^*−/−*^ mESCs ([Figure 5D](#F5){ref-type="fig"}). For the identical repeats, loss of MSH2 caused a 1.9-fold reduction in the RMD frequency for the 3.3-kbp distance but had no effect at the other distances ([Figure 5D](#F5){ref-type="fig"}). In summary, both MSH2 and BLM appear to inhibit RMDs independently of RAD52.

DISCUSSION {#S8}
==========

To understand the mechanism of RMD formation, we have examined the relative role of several factors on RMDs under varying conditions of DSB/repeat distance and sequence divergence. We found that these specific conditions can have a striking impact on the influence of individual factors on RMDs, which we have summarized in a heatmap ([Figure 6](#F6){ref-type="fig"}). In particular, we found that the BLM helicase has contrary effects on RMDs, depending on DSB/repeat distance and sequence divergence. For intermediate DSB/repeat distances and divergent repeats, BLM markedly suppresses RMDs. In contrast, for long DSB/repeat distances, BLM either promotes these events or the inhibitory effect is markedly diminished. Finally, for short DSB/repeat distances, the influence of BLM on RMDs is diminished, including for events with sequence divergence. Based on the SSA model for RMDs, we suggest that BLM promotes DSB end resection, although this role is only evident for events with long DSB/repeat distances. We also suggest that BLM promotes heteroduplex rejection; however, this role is most substantial for events with intermediate DSB/repeat distances.

A role for BLM during end resection is supported by experiments with purified proteins ([@R19]; [@R59]; [@R75]), but we did not observe an obvious effect on damage-induced chromatin-bound RPA, which is consistent with another study ([@R63]). These results may reflect the contrary roles of BLM during homologous recombination in that, by promoting heteroduplex rejection, BLM could stabilize RPA-bound end resection intermediates. In contrast, the nucleases EXO1 and DNA2, which do not appear to have an inhibitory role for RMDs, appear important for both RMDs with long DSB/ repeat distances as well as end resection (i.e., damage-induced chromatin-bound RPA), although, for RMDs with sequence divergence, we found that the requirement for DNA2 and EXO1 is diminished compared to identical repeats. The reason for this distinction is unclear, but we suggest that the rate-limiting step of RMDs with sequence divergence is evading heteroduplex rejection. Namely, although loss of EXO1 and DNA2 likely causes slow kinetics of extensive end resection, evading heteroduplex rejection could be much slower and/or infrequent, such that the influence of EXO1 and DNA2 on these events would be diminished.

Regarding specific requirements for BLM, EXO1, and DNA2, each of these factors are particularly important for RMDs with DSB/repeat distances that are ≥19 kbp. We also performed double mutant analysis and found that disrupting both EXO1 with DNA2 caused a marked reduction in RMDs at the 9.1-kbp distance. In contrast, these factors are largely dispensable for RMDs with the 16-bp and 3.3-kbp DSB/repeat lengths. These findings are consistent with a dispensable role of DNA2 for measurements of end resection between approximately 0.3--3.5 kbp, although such assays based on AsiSI-induced DSBs have not been shown to detect resection beyond this range ([@R57]; [@R91]). In contrast, EXO1 is important 0.3--3.5 kbp of end resection, based on this assay ([@R91]). Nonetheless, EXO1 has been shown to be dispensable for homologous recombination events requiring this amount of end resection (i.e., \<3 kbp; [@R16]; [@R69]).

We speculate that, in cells deficient in EXO1 and DNA2, other nucleases can mediate end resection until approximately 9 kbp. Nevertheless, end resection \<9 kb likely occurs at a reduced efficiency and/or rate in cells without EXO1 and DNA2, because end resection as measured by chromatin-bound RPA and/or the AsiSI nuclease assays is reduced in such cells. Alternatively, it is formally possible that such recombination events may have a resection-independent mechanism. This latter possibility may be unlikely, because RMDs at all DSB/repeat lengths are dependent on the end resection initiation factor CtIP ([@R19]; [@R23]; [@R48]; [@R72]). In summary, BLM, EXO1, and DNA2 in mammalian cells appear particularly important for homologous recombination events (e.g., RMD events) requiring end resection that is ≥9.1 kbp, as compared to ≤3.3 kbp.

Regarding physiological significance, such extensive resection to enable RMDs may be required under conditions where resection has initiated but HDR is not feasible, such as in the absence of the sister chromatid template ([@R38]). Because such resected ends also may not be readily repaired by end joining, RMDs may be required to ensure restoration of the chromosome at the expense of a deletion mutation between the repeats. Accordingly, facilitating RMDs is an example of cells ensuring survival at the cost of loss of genetic information ([@R42]; [@R58]).

Considering the mechanism of such resection, both the helicase and nuclease domains of DNA2 appear important for RMDs with a long DSB/repeat distance. As one possibility, the DNA2 helicase domain could be important to unwind complex DNA structures (e.g., G-quadruplex) during end resection, as is proposed for its role in DNA replication ([@R24]; [@R45]; [@R49]; [@R81]). However, we examined the sequence of the RMD reporter for possible G-quadruplex-forming repeats ([@R12]) and did not observe an obvious enrichment of such sequences far from the repeat, or of the repeats themselves (identical or divergent), but rather found a set of such sequences just upstream of the repeat ([Figure S4](#SD1){ref-type="supplementary-material"}). As an alternative mechanism, we suggest that the helicase domain of DNA2 may be important for unwinding long stretches of DNA to facilitate nucleolytic degradation by its nuclease domain and/or EXO1, which is supported by studies of the DNA2 helicase activity ([@R67]).

DSB/repeat distance not only affects the amount of end resection required for RMDs but also the length of the 3′ ssDNA that flanks the annealing intermediate (i.e., the length of the non-homologous tail). In *S. cerevisiae,* heteroduplex rejection has been shown to require such a non-homologous tail ([@R3]; [@R14]; [@R15]; [@R34]). The precise influence of the non-homologous tail on heteroduplex rejection is unclear. One proposed model is that the MSH2/MSH6 complex preferentially recruits the SGS1 helicase to heteroduplexes with a non-homologous tail ([@R3]; [@R14]; [@R15]; [@R34]). In contrast, without a non-homologous tail, SGS1 may not be recruited and/or may not unwind such substrates ([@R15]). Such MSH2-mediated heteroduplex rejection in *S. cerevisiae* requires only a very short non-homologous tail (\~30 bp; [@R3]), which is consistent with our findings that MSH2 suppresses RMDs between divergent repeats for all DSB/repeat distances.

However, for the BLM helicase, suppression of RMDs between divergent repeats is most predominant for intermediate DSB/repeat distances, indicating that BLM-mediated heteroduplex rejection functions through different parameters than MSH2. Indeed, the BLM-mediated suppression of these RMDs is not epistatic with MSH2, indicating that BLM can disrupt heteroduplex DNA independently of MSH2. We also found that the BLM helicase domain is required for inhibition of such RMDs, which is consistent with a direct role in unwinding heteroduplex DNA. This finding is not necessarily expected, because several anti-recombination functions of *SGS1* in *S. cerevisiae* have been shown to be independent of its helicase domain ([@R37]; [@R46]; [@R66]; [@R89]). BLM-mediated unwinding of heteroduplex DNA appears to be optimal for events with a long non-homologous tail, given that BLM caused the greatest suppression of RMDs with intermediate DSB/repeat distances (≥3.3 kbp). As one possible mechanism, cleavage and/or degradation of a long non-homologous tail may have slower kinetics than a shorter tail and hence may be more prone to unwinding via BLM. Alternatively, a long non-homologous tail may bind a specific factor(s), or form a particular secondary structure, that recruits BLM to the heteroduplex DNA.

The physiological significance of a long non-homologous tail is that this structure is likely a key indicator of aberrant recombination intermediates. Namely, nonallelic homologous recombination (NAHR) likely involves divergent sequences that are also flanked by a non-homologous tail ([@R11]). In contrast, this tail is absent in recombination between sister chromatids. Similarly, allelic recombination between homologous chromosomes may have sequence divergence but is unlikely to involve a long non-homologous tail. Thus, requiring both sequence divergence and a long non-homologous tail for optimal BLM function may ensure that BLM inhibits NAHR while allowing for sister chromatid and allelic recombination. Consistent with this notion, BLM does not appear to have an obvious suppressive effect on allelic recombination, apart from inhibiting crossover products ([@R44]). Finally, although we propose that the major effects of BLM on RMDs is via regulation of DSB end resection and heteroduplex rejection, it is also possible that BLM could affect the synapsis of DSB ends across long distances and/or the induction or persistence of Cas9 DSBs, although, regarding the latter, BLM depletion did not have an obvious effect on Cas9-induced mutagenic end joining.

In addition to BLM, we also found that DSB/repeat distance and repeat divergence affects the relative role of the annealing factor RAD52 during RMDs. As shown previously for RMDs between identical repeats ([@R50]), we found that RAD52 is dispensable for these events with short DSB/repeat distances (i.e., 16 bp) but promotes such events with longer distances (≥ 3.3 kbp). We found similar results with the 1% divergent repeats. As described above, 3′-DSB/repeat distances ≥3.3 kbp likely result in an annealing intermediate with a long non-homologous tail. Thus, RAD52 appears particularly important for RMDs that require removal of a long non-homologous tail, which is consistent with recent studies ([@R40]; [@R87]). As discussed above in regards to BLM function, removal of a long non-homologous tail may have slower kinetics than for a short tail. Thus, RMDs with a long non-homologous tail may require a highly stable annealing intermediate that is dependent on RAD52. This model is supported by the capacity for RAD52 to stabilize dsDNA, as detected as resistance to force-induced strand separation ([@R9]).

A corollary of this model is that other annealing factors can substitute for RAD52 for RMDs with a short non-homologous tail. Furthermore, such annealing factors also appear to substitute for RAD52 for events with long non-homologous tails but only under specific circumstances. Namely, for 1% divergent repeats and 3′-DSB/repeat distance of 3.3--9.1 kbp, RAD52 is critical for these RMDs but only in the presence of BLM and MSH2. These findings are significant, because inhibitors of RAD52 are being developed for synthetic lethal strategies ([@R35]). Namely, our findings raise the notion that such inhibitors may fail to inhibit RMD events in MSH2-deficient tumors, which appear to include both inherited colorectal cancer ([@R27]) and such tumors that downregulate mismatch repair in response to therapy ([@R71]). In addition, RAD52 is dispensable for RMDs with 3% divergent repeats, except for the 9.1-kbp DSB/repeat distance, although overexpression of RAD52 can substantially promote these events for the ≥3.3-kbp distances. Consistent with this notion, a report in human cells found that RMD events between ≥5% divergent repeats are independent of RAD52 ([@R52]).

Altogether, we suggest that RAD52 is particularly important to mediate annealing of identical and 1% divergent repeats that are flanked by a long non-homologous tail. In contrast, for events involving a short non-homologous tail, 3% sequence divergence, and/or occurring in the absence of heteroduplex rejection (i.e., with loss of BLM or MSH2), other annealing factors appear to substitute for RAD52 to mediate these events. The pathways that mediate such synapsis during RMDs are unclear, although they are unlikely to involve BRCA2, which we find suppresses RMDs, similar to previous studies ([@R50]; [@R77]; [@R84]). In conclusion, we suggest that DSB/repeat distance has a substantial influence on the mechanism of RMDs, because this distance affects both the amount of end resection required as well as the length of the non-homologous tail in the annealing intermediate, which appears critical for optimal BLM-mediated heteroduplex rejection.

STAR★METHODS {#S9}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S10}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jeremy M Stark (<jstark@coh.org>). All unique/stable reagents (e.g., plasmids and cell lines) generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement, as needed.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S11}
--------------------------------------

The model cell line for this study is male mESCs, cultured at 37°C and 5% CO~2~ on tissue culture dishes coated with 0.1% Gelatin. Standard media for mESCs was used: 500 mL DMEM high glucose supplemented with L-Glutamine, 6 mL 100X non-essential amino acids, 75 mL Stasis Fetal Bovine Serum, 45 μL of Mouse Leukemia Inhibitory Factor, 4.3 μL2-Mercaptoethanol, 6 mL 100X Penicillin/Streptomycin, and 120 μL Plasmocin.

Several mESC lines were previously described: WT J1 ([@R50]), *Blm*^*tet/tet*^ ([@R90]), *Msh2−/−* ([@R17]; [@R50]), *Exo1−/−* ([@R16]), and *Rad52−/−* ([@R50]). The *Rad52−/−Msh2−/−* mESC line was derived from the *Rad52−/−* cell line, using two Cas9-mediated DSBs to induce a deletion in *Msh2* using two sgRNAs (Msh2 sgRNA 1 and 2, [Table S1](#SD1){ref-type="supplementary-material"}). Cells were transfected with these plasmids and dsRED2-N1, as with the reporter assays (see below), and sorted for dsRED+ cells as described ([@R40]), which were plated at low density. Clones were first screened for a deletion mutation with PCR (primers Msh2 screening P1 and P2, [Table S1](#SD1){ref-type="supplementary-material"}), and then by MSH2 immunoblotting.

METHOD DETAILS {#S12}
--------------

### Reporter integration and recombinant DNA {#S13}

Cas9 and sgRNAs were expressed from the px330 plasmid (Addgene 42230, deposited by Dr. Feng Zhang) ([@R68]). The reporter plasmids RMD-GFP, 1%-RMD-GFP, 3%-RMD-GFP, and Pim-DR-GFP were previously described ([@R50]; [@R54]). The reporter plasmids were integrated into the *Pim1* locus of mESCs using electroporation of linerarized plasmid, selection in hygromycin, and screening by PCR, as described previously ([@R6]). For the *Blm*^*tet/tet*^ cells, we included in the electroporation a px330 plasmid with an sgRNA targeting the *Pim1* locus (Pim1 sgRNA 1, [Table S1](#SD1){ref-type="supplementary-material"}) to promote gene targeting. For these *Blm*^*tet/tet*^ reporter cell lines, the untargeted *Pim1* locus surrounding the sgRNA target site was amplified for sequencing with primers Pim1 screening P1 and P2 ([Table S1](#SD1){ref-type="supplementary-material"}).

The sgRNA target sequences for inducing DSBs in the reporters were described previously ([@R50]; [@R56]) ([Table S1](#SD1){ref-type="supplementary-material"}). The plasmids pCAGGS-V5-RAD52, pCAGGS-MSH2, pCAGGS-NZE-GFP (GFP expression vector), pgk-puro, and pCAGGS-BSKX empty vector (EV) were described previously ([@R33]; [@R50]). pCAGGS-EXO1 was generated by inserting the EXO1 coding region from Mammalian Gene Collection clone number 5686 into pCAGGS-BSKX. pCAGGS-3xFlag-DNA2 WT, D277A, K654A, and D277A/K654A were generated from Addgene plasmids \# 31955, 31956, 31957, and 31958, respectively, which were deposited by Dr. Sheila Stewart ([@R24]; [@R45]; [@R67]). pCAGGS-BLM WT was generated from Addgene plasmid \#127641, which was deposited by Dr. Nicolas Manel ([@R30]). The EXO1-D173A ([@R61]) and BLM-K695A/795A ([@R88]) mutants were generated using the QuikChange kit. For siRNA reagents, we used the following reagents from Dharmacon ([Table S1](#SD1){ref-type="supplementary-material"}): non-targeting siCTRL (D-001810--01-20), siBLM (pool of 4, D-061987--01, −02, −03, −04), siDNA2 (pool of 4, D-062864--01, −02, −03, −04), siCtIP (pool of 4, D-055713--14, −15, −16, −17) and siBRCA2 (pool of 4, J-042993--05, −06, −07, −08). The pools of siRNAs contain each of the four in equal amounts.

### RMD and HDR reporter assays {#S14}

For the RMD assays including siRNA, mESC cells were seeded on a mixture of 3.75 pmol of each siRNA pool using RNAiMAX at a cell density of 0.5 × 10^5^ cells per well of a 24-well plate, with 0.5 ml of antibiotic-free media. The next day, each well was transfected with 200 ng of each sgRNA/Cas9 plasmid plus 3.75 pmol of each siRNA pool using Lipofectamine 2000, with 0.5 ml of antibiotic-free media. For the RMD assays with complementation vectors, transfections with siRNA included 200 ng of complementation vector, and transfections without siRNA included 100 ng of complementation vector. The EV control (pCAGGS-BSKX) was used to ensure equal total plasmid concentration per experiment. For RMD assays with *Blm*^*tet/tet*^ mESCs, cells were seeded at 0.25 × 10^5^ cells on 24-well plates in either DMSO or Dox (1 μg/mL) two days prior to transfection with the sgRNA/Cas9 plasmids and 200 ng of EV, followed by DMSO or Dox (1 μg/mL) treatment until analysis. For RNAi experiments with the *Blm*^*tet/tet*^ mESCs, 5 pmol of siRNA was used in place of EV. For DR-GFP analysis with siBRCA2, cells were transfected with a px330 plasmid expressing an sgRNA targeting DR-GFP ([Table S1](#SD1){ref-type="supplementary-material"}) ([@R55]), 200 ng of EV, and 5 pmol of siRNA. For the DR-GFP experiment in *Blm*^*tet/tet*^ mESCs, cells were plated and treated as for the RMD assays. Each experiment included parallel transfections with the GFP expression vector (pCAGGS-NZE-GFP) to normalize repair frequencies to transfection efficiency. For all reporter assays, three days after transfection, cells were analyzed by flow cytometry using a CyAn-ADP (Dako), as described ([@R33]).

### End resection assay {#S15}

Cells were pre-treated with siRNAs using RNAiMAX transfection, using the same concentration of siRNA as for the reporter assays, but scaled four-fold to a well of a 6-well plate, and cultured for two days prior to a one-hour treatment with 3 μM Etoposide or vehicle control (DMSO). Cells were then assayed for chromatin-bound (i.e., mild-detergent resistant) RPA staining, as described ([@R28]). Specifically, cells were detergent extracted in 100 μL of 0.2% Triton X-100 in PBS on ice for 10 minutes, and washed with 1 mL of BSA-PBS (0.1% BSA in PBS). Next, cells were fixed with 100 μL BD Cytofix/Cytoperm buffer for 15 min, washed with BSA-PBS, and incubated in 50 μL of BD Perm/Wash buffer with 1:800 rat monoclonal anti-RPA32 antibody for 1 hour. Cells were washed with BSA-PBS and re-suspended in 50 μL BD Perm/Wash buffer with 1:200 secondary antibody (goat anti-Rat IgG, Alexa Fluor 488) for 30 min. Finally, cells were washed with BSA-PBS and re-suspended in 0.3 mL PBS with 0.02% sodium azide, 250 μg/ml RNase A, and 2 μg/ml DAPI for 30 min at 37°C. Stained cells were analyzed on a CyAn-ADP (Dako) flow cytometer. For consistent analysis, the gate for high RPA staining was set as the top \~5% RPA+ population of the control (DMSO treated) sample for each cell line and experiment.

### Immunoblotting and RT-PCR {#S16}

For immunoblotting analysis, cells were transfected using the same total siRNA and plasmid concentrations as for the reporter assays, but using EV instead of sgRNA/Cas9 plasmids. For analysis of siBLM treated cells, following the pre-treatment with siRNA using RNAiMAX, cells were transfected with pgk-puro plasmid (1200 ng), EV (400 ng), and siRNA (15 pmol). The next day, cells were re-plated into puromycin (1.5 μg/mL) and cultured for one day to enrich for transfected cells. For *Blm*^*tet/tet*^ mESCs, cells were pre-treated with DMSO or Dox (1 μg/ mL) for two days until protein extraction. To examine siBRCA2 treated cells, WT or *Blm*^*tet/tet*^ mESCs, the latter of which were pre-treated with DMSO or Dox as for the reporter assays, were transfected with pgk-puro plasmid (1200 ng), EV (400 ng), and 20 pmol of siRNA. The next day, cells were re-plated into puromycin (3 μg/mL) and cultured for one day to enrich for transfected cells. For BLM, RAD52, CtIP, and MSH2 analysis, cells were lysed using NETN buffer (20 mM Tris at pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Igepal, 1.25 mM DTT, Roche protease inhibitor) with several freeze/thaw cycles. For EXO1, BRCA2, and 3xFlag-DNA2 analysis, cells were lysed in ELB buffer (250 mM NaCI, 5 mM EDTA, 50 mM HEPES, 0.1% Ipegal, Roche protease inhibitor) with sonication (Qsonica, Q800R). Extracts were probed with antibodies for rabbit polyclonal anti-BLM, rabbit polyclonal anti-BRCA2, mouse monoclonal anti-CtIP, rabbit polyclonal anti-EXO1, mouse monoclonal anti-FLAG HRP, rabbit polyclonal anti-RAD52, rabbit polyclonal anti-MSH2, rabbit polyclonal anti-ACTIN, and secondary antibodies (goat polyclonal Anti-Mouse IgG HRP, and goat polyclonal Anti-Rabbit IgG HRP). ECL western blotting substrate was used to develop HRP signals. For quantitative RT-PCR analysis to examine DNA2 mRNA, two days after siRNA treatment, total RNA was isolated with the RNAeasy kit and reverse transcribed with MMLV-RT. The RT reactions were amplified with primers for DNA2 (DNA2 RT-PCR P1 and P2), and ACTIN (ACTIN RT-PCR P1 and P2) ([Table S1](#SD1){ref-type="supplementary-material"}), using SYBR Select Master Mix and quantified on Applied Biosystems 7900HT. Relative levels of DNA2 mRNA were determined using the cycle threshold (Ct) value for DNA2 for individual PCR reactions subtracted by Ct value for the ACTIN control (ΔCt value), which was then subtracted from the corresponding ΔCt from siCTRL treated cells (ΔΔCt), which was used to calculate 2^ΔΔCt^ for the fold-change.

### Cell cycle analysis, Surveyor nuclease assay, and G-quandruplex predictions {#S17}

To examine cell cycle phase, cells were incubated with 10 μM bromodeoxyuridine (BrdU) for 30 minutes, fixed with 70% Ethanol, and stained with mouse monoclonal anti-BrdU FITC antibody, propidium iodine, and RNase A. Staining was evaluated using a CyAn ADP Analyzer (Dako). Mutagenic end joining frequencies were determined for cells transfected as for the reporter experiments, using the Cas9/sgRNA plasmid targeting the 19 kbp DSB/repeat distance. Genomic DNA was isolated and examined with the Surveyor Mutation Detection Kit, as described, using the primers Surveyor P1 and P2 ([Table S1](#SD1){ref-type="supplementary-material"}) ([@R50]). Predictions for G-quadruplex forming repeats was performed with the non-B DNA Motif Search Tool ([@R12]).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S18}
---------------------------------------

Data are shown as the mean ± standard deviation (SD). Statistical comparisons were performed with unpaired two-tailed Student's t tests with the Holm-Sidak correction for multiple comparisons, without assuming a consistent SD, using GraphPad Prism software. The number of replicates (n), and definition of significance (minimum *P value* ≤ 0.05), are each described in the figure legends.

DATA AND CODE AVAILABILITY {#S19}
--------------------------

The published article includes all datasets generated or analyzed during this study.
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![BLM Promotes RMDs Induced by Chromosomal DSBs Far from a Homologous Repeat but Markedly Suppresses RMDs with Intermediate DSB/Repeat Distances, Particularly with Divergent Repeats\
(A) A schematic of the RMD-GFP reporter with two repeats on chromosome 17 of mouse embryonic stem cells (mESCs). An RMD causes GFP expression. 1%-RMD-GFP and 3%-RMD-GFP have 1% and 3% sequence divergence between the repeats, respectively. RMDs are induced with two sgRNA/Cas9-mediated DSBs: one DSB is 268 bp downstream of the 5′ repeat, and the second DSB is various distances upstream of the 3′ repeat.\
(B) Immunoblotting analysis of BLM and ACTIN In WT mESCs treated with siBLM, *Blm*^*tet/tet*^ mESCs with Dox treatment, and control treatments with siCTRL or DMSO.\
(C) Effects of siBLM treatment on RMDs. n = 6. \*p ≤ 0.0119 for siBLM versus siCTRL. Shown are fold effects of significant differences, using the mean.\
(D) RMDs in *Blm*^*tet/tet*^ mESCs treated with Dox (BLM depleted) versus DMSO (BLM overexpression versus WT). n = 6. \*p ≤ 0.0229 for Dox versus DMSO. Fold effects as in (C) are shown.](nihms-1568954-f0001){#F1}

![The DSB End Resection Factors EXO1 and DNA2 Are Particularly Important for RMDs with Long 3′-DSB/Repeat Distances, Similar to BLM\
(A) Effects of siDNA2 treatment on RMDs. n = 6. \*p ≤ 0.0374 and †p-unadjusted ≤ 0.0355 for siCTRL versus siDNA2. Shown are fold effects of significant differences, using the mean.\
(B) RT-PCR analysis of DNA2 mRNA in WT mESCs treated with siDNA2 or siCTRL. n = 3 PCR. \*p = 0.0124.\
(C) Effects of 3xFLAG-DNA2 expression vectors on the 28.4-kbp RMD with identical repeats in cells treated with siDNA2. n = 6.\*p ≥ 0.041 versus siDNA2 EV. Immunoblotting analysis of FLAG and ACTIN using these vectors. Fold effects as in (A) are shown.\
(D) RMD frequencies for WT (EV), *Exo1*^*−/−*^ mESCs (EV), and *Exo1*^*−/−*^ mESCs transfected with an EXO1 expression vector (EXO1). n = 6. \*p ≤ 0.0042 and †p-unadjusted = 0.0388 for *Exo1*^*−/−*^ versus WT and for *Exo1*^*−/−*^ EV versus EXO1 complemented. Fold effects as in (A) are shown.\
(E) Effects of EXO1-D173A versus WT on the 28.4-kbp RMD with identical repeats in *Exo1*^*−/−*^ mESCs. n = 6. \*p \< 0.0001 versus *Exo1*^*−/−*^ EV. WT EV frequencies are from (D). Fold-effects as in (A) are shown. Immunoblotting analysis of EXO1 and ACTIN using these vectors is shown.](nihms-1568954-f0002){#F2}

![The Influence of EXO1 on Promoting RMDs Is Not Epistatic with the Effect of DNA2 and BLM and Is Consistent with a Role in End Resection\
(A) RT-PCR of DNA2 mRNA and immunoblotting analysis of BLM and ACTIN of *Exo1*^*−/−*^ mESCs treated with the respective siRNAs. n = 3 PCR. \*p = 0.052.\
(B) RMD analysis of *Exo1*^*−/−*^ mESCs treated with siCTRL, siDNA2, or siBLM along with WT(siCTRL). n = 6. \*p ≤ 0.0179 *Exo1*^*−/−*^ siCTRL versus siDNA2 and *Exo1*^*−I−*^ siCTRL versus WT siCTRL. \*p ≤ 0.0435 and †p-unadjusted = 0.0274 for *Exo1−I−* siCTRL versus siBLM. Shown are fold effects of significant differences, using the mean.\
(C) Influence of DNA2, BLM, and EXO1 on etoposide-induced chromatin-bound RPA. Cells were incubated with 3 μM etoposide or DMSO control, detergent extracted, and stained for RPA and DAPI. Shown are representative flow cytometry plots with the upper gate showing high RPA staining (upper) and percentages of cells with such staining (lower). n = 3 for DMSO. For etoposide treated, n = 12 for siCTRL, n = 8 for siDNA2, and n = 4 for siBLM. \*p \< 0.001.](nihms-1568954-f0003){#F3}

![BLM-Mediated Suppression of RMDs Is Not Epistatic with the Influence of MSH2 (except at the 16-bp Distance) or BRCA2\
(A) Influence of BLM depletion on RMDs in *Msh2*^*−/−*^ mESCs. Shown is BLM and ACTIN immunoblot analysis, and RMD frequencies, of *Msh2*^*−/−*^ mESCs treated with siBLM versus siCTRL. The WT siCTRL RMD frequencies are from [Figure 1C](#F1){ref-type="fig"}. n = 6. \*p ≤ 0.0222 and †p-unadjusted ≤ 0.0272 for siCTRL versus siBLM in *Msh2*^*−/−*^ mESCs or for WT versus *Msh2*^*−/−*^. Shown are fold effects of significant differences, using the mean.\
(B) Influence of BLM levels on HDR (DR-GFP assay) In *Blm*^*tet/tet*^ mESCs treated with DMSO or Dox, as for the RMD assays. n = 6. ns, not significant.\
(C) Influence of siBRCA2 treatment on HDR in mESCs. n = 6. \*p = 0.0002. Immunoblot analysis of BRCA2 and ACTIN using this siRNA is shown. The asterisk (\*) indicates nonspecific bands.\
(D) Immunoblot analysis of BRCA2 depletion in *Blm*^*tet/tet*^ mESCs treated with DMSO or Dox.\
(E) Effects of siBRCA2 on RMDs in *Blm*^*tet/tet*^ mESCs treated with Dox (i.e., BLM depletion) or DMSO control. n = 6. \*p ≤ 0.0354 and †p-unadjusted ≤ 0.0435 for siCTRL versus siBRCA2. Fold effects as in (A) are shown.](nihms-1568954-f0004){#F4}

![RAD52 Substantially Promotes a Subset of RMDs; however, BLM and MSH2 Inhibit RMDs Independently of RAD52\
(A) Immunoblotting analysis for several mESC lines, and transfections of siRNA or complementation vectors, for RAD52, MSH2, BLM, and ACTIN.\
(B) RMD analysis in WT (EV), *Rad52*^*−/−*^ (EV), and *Rad52*^*−/−*^ mESCs transfected with a RAD52 expression vector. Frequencies for WT EV are from [Figure 2D](#F2){ref-type="fig"}. n = 6. \*p ≤ 0.0481 and †p-unadjusted ≤ 0.0332 for EV versus RAD52 complemented in *Rad52*^*−/−*^ or WT versus *Rad52*^*−/−*^.\
(C) RMD frequencies of *Rad52*^*−/−*^ mESCs treated with siBLM or siCTRL. Frequencies from WT siCTRL are from [Figure 1C](#F1){ref-type="fig"}. n = 6. \*p ≤ 0.0036 for siCTRL versus siBLM or for WT versus *Rad52*^*−/−*^.\
(D) RMD analysis for WT, *Rad52*^*−/−*^ mESCs, *Rad52*^*−/−*^*Msh2*^*−/−*^, and *Rad52*^*−/−*^*Msh2*^*−/−*^ transfected with an MSH2 expression vector. Frequencies for WT EV and *Rad52*^*−/−*^ EV are from [Figure 2D](#F2){ref-type="fig"} and (B), respectively. n = 6. \*p ≤ 0.0221 for *Rad52*^*−/−*^ versus *Rad52*^*−/−*^*Msh2*^*−/−*^ or for MSH2 complemented versus EV.](nihms-1568954-f0005){#F5}

![Summary of Effects of Individual Factors on RMDs\
Shown are two heatmaps with the fold effects of individual factors on RMDs (versus the WT control) at distinct DSB/repeat distances and between identical and divergent repeats. The BLM fold effects shown are siBLM versus siCTRL.](nihms-1568954-f0006){#F6}

  REAGENT or RESOURCE                                            SOURCE                                                                  IDENTIFIER
  -------------------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------
  Antibodies                                                                                                                             
  Rat monoclonal anti-RPA32                                      Cell Signaling                                                          Cat\#2208; RRID:AB_2238543
  Rabbit polyclonal anti-BLM                                     Bethyl Laboratories                                                     Cat\#A300-110A; RRID:AB_2064794
  Rabbit polyclonal anti-BRCA2                                   Abcam                                                                   Cat\#ab27976; RRID:AB_2067760
  Mouse monoclonal anti-CtIP                                     Active Motif                                                            Cat\#61141, RRID:AB_2714164
  Rabbit polyclonal anti-EXO1                                    Bethyl Laboratories                                                     Cat\#A302-640A; RRID:AB_10567122
  Rabbit polyclonal anti-RAD52                                   ABclonal                                                                Cat\#A3077; RRID:AB_276488
  Rabbit polyclonal anti-MSH2                                    Bethyl Laboratories                                                     Cat\# A300-452A; RRID:AB_420918
  Rabbit polyclonal anti-ACTIN                                   Sigma-Aldrich                                                           Cat\#A2066; RRID:AB_476693
  Mouse monoclonal anti-FLAG HRP                                 Sigma-Aldrich                                                           Cat\#A8592; RRID:AB_439702
  Goat anti-Rat IgG, Alexa Fluor 488                             Thermo Fisher                                                           Cat\#A-11006; RRID:AB_141373
  Mouse monoclonal Anti-BrdU, FITC                               Becton Dickinson                                                        Cat\#556028; RRID:AB_396304
  Goat polyclonal Anti-Mouse IgG, HRP                            Abcam                                                                   Cat\#ab205719; RRID:AB_2755049
  Goat polyclonal Anti-Rabbit IgG, HRP                           Abcam                                                                   Cat\#ab205718
  Chemicals, Peptides, and Recombinant Proteins                                                                                          
  Doxycycline hyclate                                            Sigma Aldrich                                                           Cat\#D9891
  Lipfectamine 2000                                              Themo Fisher                                                            Cat\#11668019
  Lipfectamine RNAiMAX                                           Thermo Fisher                                                           Cat\#13778150
  BD Cytofix/Cytoperm buffer                                     Becton Dickinson                                                        51-2090KZ
  BD Perm/Wash buffer                                            Becton Dickinson                                                        51-2091KZ
  RNase A                                                        Sigma Aldrich                                                           Cat\#R4642
  DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride)           Sigma Aldrich                                                           Cat\#D8417
  MMLV Reverse Transcriptase                                     Promega                                                                 Cat\#M170A
  SYBR Select Master Mix                                         Thermo Fisher                                                           Cat\#4472908
  Etoposide                                                      Sigma Aldrich                                                           Cat\#E1383
  propidium iodine                                               Sigma Aldrich                                                           Cat\#P4170
  bromodeoxyuridine                                              Becton Dickinson                                                        Cat\#51-2420KC
  Mouse Leukemia Inhibitory Factor                               Gemini                                                                  Cat\#400-495 10\^7
  2-Mercaptoethanol                                              Sigma Aldrich                                                           Cat\#M6250
  DMEM high glucose supplemented with L-Glutamine                Corning                                                                 Cat\#10-017-CV
  non-essential amino acids                                      Irvine Scientific                                                       Cat\#9304
  Penicillin/Streptomycin                                        Corning                                                                 Cat\#30-002-C1
  Plasmocin                                                      Invivogen                                                               Cat\#ant-mpt
  hygromycin                                                     Thermo Fisher                                                           Cat\#10687010
  puromycin                                                      Sigma Aldrich                                                           Cat\#P8833
  Protease inhibitor                                             Roche                                                                   Cat\#11836153001
  Igepal                                                         Sigma Aldrich                                                           Cat\#I8896
  Dimethyl sulfoxide                                             Sigma Aldrich                                                           Cat\#D2650
  Triton X-100                                                   USB                                                                     Cat\#22686
  Gelatin                                                        Sigma Aldrich                                                           Cat\#G1890
  Critical Commercial Assays                                                                                                             
  RNAeasy Plus Kit                                               QIAGEN                                                                  Cat\#74134
  ECL western blotting substrate                                 Thermo Fisher                                                           Cat\#32106
  Surveyor Mutation Detection Kit                                Integrated DNA Technologies                                             Cat\#706020
  Experimental Models: Cell Lines                                                                                                        
  WT mESC J1 strain                                              ATCC                                                                    Cat\#SCRC-1010
  *Blm^tet/tet^* mESC line                                       [@R90]                                                                  N/A
  *Rad52−/−* mESC line                                           [@R50]                                                                  N/A
  *Msh2−/−* mESC line                                            [@R17]                                                                  N/A
  *Rad52−/−Msh2−/−* mESC line                                    This study                                                              N/A
  *Exo1−/−* mESC line                                            [@R16]                                                                  N/A
  Oligonucleotides                                                                                                                       
  Oligonucleotide sequences for sgRNAs, siRNA, and PCR primers   See [Table S1](#SD1){ref-type="supplementary-material"} for sequences   N/A
  Recombinant DNA                                                                                                                        
  RMD-GFP reporter plasmid                                       [@R50]                                                                  N/A
  1%-RMD-GFP reporter plasmid                                    [@R50]                                                                  N/A
  3%-RMD-GFP reporter plasmid                                    [@R50]                                                                  N/A
  Pim-DR-GFP reporter plasmid                                    [@R54]                                                                  N/A
  px330 sgRNA/Cas9 expression vector                             Addgene                                                                 Cat\#42230
  pCAGGS-BSKX empty expression vector                            [@R33]                                                                  N/A
  pgk-puro                                                       [@R33]                                                                  N/A
  pCAGGS-NZE-GFP (GFP expression vector)                         [@R33]                                                                  N/A
  pCAGGS-EXO1 WT                                                 This study                                                              N/A
  pCAGGS-EXO1-D173A                                              This study                                                              N/A
  pCAGGS-3xFlag-DNA2 WT                                          This study                                                              N/A
  pCAGGS-3xFlag-DNA2 D277A                                       This study                                                              N/A
  pCAGGS-3xFlag-DNA2 K654A                                       This study                                                              N/A
  pCAGGS-3xFlag-DNA2 D277A/K654A                                 This study                                                              N/A
  pCAGGS-BLM WT                                                  This study                                                              N/A
  pCAGGS-BLM K695A/K795A                                         This study                                                              N/A
  dsRED2-N1                                                      Clontech                                                                Cat\#632406
  Software and Algorithms                                                                                                                
  GraphPad Prism                                                 GraphPad                                                                N/A
  non-B DNA Motif Search Tool                                    [@R12]                                                                  N/A

###### Highlights

-   DNA break/repeat distance and repeat divergence specify RMD mechanisms

-   BLM, EXO1, and DNA2 mediate RMDs with remarkably long DNA break/repeat distances

-   BLM heteroduplex rejection is optimal with a long non-homologous tail

-   BLM heteroduplex rejection is independent of MSH2 and RAD52
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